Naveen Pemmaraju: Blastic Plasmacytoid Dendritic Cell Neoplasm treatment with focus on SCT

Naveen Pemmaraju shared a post about a recent paper titled “How I treat Blastic Plasmacytoid Dendritic Cell Neoplasm” published in Blood Journal. Read his post on X below:

Authors: Mohamed Kharfan-Dabaja, Andrew Lane, Naveen Pemmaraju.

“Proud to share our brand new paper just out in Blood Journal collaborative multi-disciplinary How I Treat BPDCN with focus on SCT.”

More posts featuring Naveen Pemmaraju.

Naveen Pemmaraju is a Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center (MDACC) and Executive Director of MDACC Network. He is also the Leukemia Hematology/Oncology Course Director.

His research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), MPN and AML.